{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:40:51Z","timestamp":1792194051666,"version":"4.4.0"},"reference-count":255,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01857-9","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:47:26Z","timestamp":1792190846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The advances and challenges of mRNA-LNP application in fields of hematology and oncology therapeutics"],"prefix":"10.1186","volume":"19","author":[{"given":"Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"1857_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z 1 Wang","year":"2021","unstructured":"1 Wang Z, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616\u201322. https:\/\/doi.org\/10.1038\/s41586-021-03324-6.","journal-title":"Nature"},{"key":"1857_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR 2 Baden","year":"2021","unstructured":"2 Baden LR, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"N Engl J Med"},{"key":"1857_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(26)00512-x","author":"AK 3 Blakney","year":"2026","unstructured":"3 Blakney AK, et al. Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective. Lancet (London England). 2026. https:\/\/doi.org\/10.1016\/s0140-6736(26)00512-x.","journal-title":"Lancet (London England)"},{"key":"1857_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00285-2","author":"F 4 Kreier","year":"2022","unstructured":"4 Kreier F. Ten billion COVID vaccinations: world hits new milestone. Nature. 2022. https:\/\/doi.org\/10.1038\/d41586-022-00285-2.","journal-title":"Nature"},{"key":"1857_CR5","doi-asserted-by":"publisher","unstructured":"5 Chen S, et al. Nanotechnology-based mRNA vaccines. Nat reviews methods primers. 2023;3. https:\/\/doi.org\/10.1038\/s43586-023-00246-7.","DOI":"10.1038\/s43586-023-00246-7"},{"key":"1857_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-026-01459-7","author":"KR 6 Chien","year":"2026","unstructured":"6 Chien KR, Foo KS, Witman N. Towards mRNA therapeutics 2.0. Nat Rev Drug Discovery. 2026. https:\/\/doi.org\/10.1038\/s41573-026-01459-7.","journal-title":"Nat Rev Drug Discovery"},{"key":"1857_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41565-023-01563-4","volume":"19","author":"J 7 Kim","year":"2024","unstructured":"7 Kim J, Eygeris Y, Ryals RC, Jozi\u0107 A, Sahay G. Strategies for non-viral vectors targeting organs beyond the liver. Nat Nanotechnol. 2024;19:428\u201347. https:\/\/doi.org\/10.1038\/s41565-023-01563-4.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR8","doi-asserted-by":"publisher","unstructured":"8, Tarab-Ravski D et al. Delivery of therapeutic RNA to the bone marrow in multiple myeloma using CD38-targeted lipid nanoparticles. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10, e2301377. https:\/\/doi.org\/10.1002\/advs.202301377.","DOI":"10.1002\/advs.202301377"},{"key":"1857_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","volume":"19","author":"X 9 Lian","year":"2024","unstructured":"9 Lian X, et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat Nanotechnol. 2024;19:1409\u201317. https:\/\/doi.org\/10.1038\/s41565-024-01680-8.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s41551-025-01511-8","volume":"9","author":"DD 10 Kang","year":"2025","unstructured":"10 Kang DD, et al. Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level. Nat biomedical Eng. 2025;9:1591\u2013609. https:\/\/doi.org\/10.1038\/s41551-025-01511-8.","journal-title":"Nat biomedical Eng"},{"key":"1857_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S 11 Qin","year":"2022","unstructured":"11 Qin S, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target therapy. 2022;7:166. https:\/\/doi.org\/10.1038\/s41392-022-01007-w.","journal-title":"Signal Transduct Target therapy"},{"key":"1857_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12967-023-04553-1","volume":"21","author":"Y 12 Zhao","year":"2023","unstructured":"12 Zhao Y, Gan L, Ke D, Chen Q, Fu Y. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy. J translational Med. 2023;21:693. https:\/\/doi.org\/10.1186\/s12967-023-04553-1.","journal-title":"J translational Med"},{"key":"1857_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","volume":"25","author":"A 13 Bot","year":"2026","unstructured":"13 Bot A, et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 2026;25:116\u201337. https:\/\/doi.org\/10.1038\/s41573-025-01291-5.","journal-title":"Nat Rev Drug Discov"},{"key":"1857_CR14","doi-asserted-by":"publisher","first-page":"e2307796121","DOI":"10.1073\/pnas.2307796121","volume":"121","author":"CA 14 Tsuchida","year":"2024","unstructured":"14 Tsuchida CA, Wasko KM, Hamilton JR, Doudna JA. Targeted nonviral delivery of genome editors in vivo. Proc Natl Acad Sci USA. 2024;121:e2307796121. https:\/\/doi.org\/10.1073\/pnas.2307796121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1857_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41586-025-10004-2","volume":"651","author":"U 15 Sahin","year":"2026","unstructured":"15 Sahin U, et al. Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature. 2026;651:1088\u201396. https:\/\/doi.org\/10.1038\/s41586-025-10004-2.","journal-title":"Nature"},{"key":"1857_CR16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/s0140-6736(23)02268-7","volume":"403","author":"JS 16 Weber","year":"2024","unstructured":"16 Weber JS, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet (London England). 2024;403:632\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(23)02268-7.","journal-title":"Lancet (London England)"},{"key":"1857_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL 17 Hunter","year":"2025","unstructured":"17 Hunter TL, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Sci (New York N Y). 2025;388:1311\u20137. https:\/\/doi.org\/10.1126\/science.ads8473.","journal-title":"Sci (New York N Y)"},{"key":"1857_CR18","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ymthe.2026.02.020","volume":"34","author":"VT 18 Lemgart","year":"2026","unstructured":"18 Lemgart VT, et al. Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies. Mol therapy: J Am Soc Gene Therapy. 2026;34:2621\u201336. https:\/\/doi.org\/10.1016\/j.ymthe.2026.02.020.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"key":"1857_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41551-025-01480-y","volume":"10","author":"S 19 Xu","year":"2026","unstructured":"19 Xu S, et al. In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery. Nat biomedical Eng. 2026;10:473\u201389. https:\/\/doi.org\/10.1038\/s41551-025-01480-y.","journal-title":"Nat biomedical Eng"},{"key":"1857_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K 20 Kariko","year":"2005","unstructured":"20 Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165\u201375. https:\/\/doi.org\/10.1016\/j.immuni.2005.06.008.","journal-title":"Immunity"},{"key":"1857_CR21","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1093\/nar\/gkq347","volume":"38","author":"BR 21 Anderson","year":"2010","unstructured":"21 Anderson BR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38:5884\u201392. https:\/\/doi.org\/10.1093\/nar\/gkq347.","journal-title":"Nucleic Acids Res"},{"key":"1857_CR22","doi-asserted-by":"publisher","unstructured":"22 Yu H, et al. An engineered linear cap-independent mRNA vaccine with intrinsic adjuvanticity induces potent anti-tumor immunity in mice. Nat Commun. 2026;17. https:\/\/doi.org\/10.1038\/s41467-026-69972-2.","DOI":"10.1038\/s41467-026-69972-2"},{"key":"1857_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02891-7","author":"SJ Jung","year":"2025","unstructured":"Jung SJ, et al. RNA stability enhancers for durable base-modified mRNA therapeutics. Nat Biotechnol. 2025. https:\/\/doi.org\/10.1038\/s41587-025-02891-7.","journal-title":"Nat Biotechnol"},{"key":"1857_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12985-025-03059-0","volume":"23","author":"H 24 Liu","year":"2026","unstructured":"24 Liu H, et al. Optimization of untranslated regions enhances antigen expression and immunogenicity of FMDV P12A3C mRNA vaccine. Virol J. 2026;23:31. https:\/\/doi.org\/10.1186\/s12985-025-03059-0.","journal-title":"Virol J"},{"key":"1857_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-026-01463-3","author":"Y 25 Xu","year":"2026","unstructured":"25 Xu Y, et al. Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses. NPJ vaccines. 2026. https:\/\/doi.org\/10.1038\/s41541-026-01463-3.","journal-title":"NPJ vaccines"},{"key":"1857_CR26","doi-asserted-by":"publisher","first-page":"102969","DOI":"10.1016\/j.omtn.2026.102969","volume":"37","author":"JJ 26 Minnell","year":"2026","unstructured":"26 Minnell JJ, Vink JNA, McKenzie RE. Unlocking translational resilience for mRNA vaccines by viral UTRs. Mol therapy Nucleic acids. 2026;37:102969. https:\/\/doi.org\/10.1016\/j.omtn.2026.102969.","journal-title":"Mol therapy Nucleic acids"},{"key":"1857_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C 27 Zhang","year":"2019","unstructured":"27 Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA Vaccines for Infectious Diseases. Front Immunol. 2019;10:594. https:\/\/doi.org\/10.3389\/fimmu.2019.00594.","journal-title":"Front Immunol"},{"key":"1857_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S 28 Linares-Fern\u00e1ndez","year":"2020","unstructured":"28 Linares-Fern\u00e1ndez S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA Vaccine to Balance Innate\/Adaptive Immune Response. Trends Mol Med. 2020;26:311\u201323. https:\/\/doi.org\/10.1016\/j.molmed.2019.10.002.","journal-title":"Trends Mol Med"},{"key":"1857_CR29","doi-asserted-by":"publisher","unstructured":"29 Jiao X et al. Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol 16, e1992, https:\/\/doi.org\/10.1002\/wnan.1992.","DOI":"10.1002\/wnan.1992"},{"key":"1857_CR30","doi-asserted-by":"publisher","first-page":"105032","DOI":"10.1016\/j.chemphyslip.2020.105032","volume":"235","author":"F 30 Ponti","year":"2021","unstructured":"30 Ponti F, Campolungo M, Melchiori C, Bono N, Candiani G. Cationic lipids for gene delivery: many players, one goal. Chem Phys Lipids. 2021;235:105032. https:\/\/doi.org\/10.1016\/j.chemphyslip.2020.105032.","journal-title":"Chem Phys Lipids"},{"key":"1857_CR31","doi-asserted-by":"publisher","first-page":"109526","DOI":"10.1016\/j.bioorg.2026.109526","volume":"171","author":"W 31 Dai","year":"2026","unstructured":"31 Dai W, et al. Design and synthesis of novel ionizable lipids enables highly efficient mRNA delivery via lipid nanoparticles. Bioorg Chem. 2026;171:109526. https:\/\/doi.org\/10.1016\/j.bioorg.2026.109526.","journal-title":"Bioorg Chem"},{"key":"1857_CR32","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM, Patisiran. First Global Approval. Drugs. 2018;78:1625\u201331. https:\/\/doi.org\/10.1007\/s40265-018-0983-6.","journal-title":"Drugs"},{"key":"1857_CR33","doi-asserted-by":"publisher","first-page":"e202200906","DOI":"10.1002\/chem.202200906","volume":"28","author":"F 33 Saadati","year":"2022","unstructured":"33 Saadati F, Cammarone S, Ciufolini MA. A Route to Lipid ALC-0315: a Key Component of a COVID-19 mRNA Vaccine. Chemistry. 2022;28:e202200906. https:\/\/doi.org\/10.1002\/chem.202200906.","journal-title":"Chemistry"},{"key":"1857_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","volume":"8","author":"L 34 Zhang","year":"2023","unstructured":"34 Zhang L, et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ vaccines. 2023;8:156. https:\/\/doi.org\/10.1038\/s41541-023-00751-6.","journal-title":"NPJ vaccines"},{"key":"1857_CR35","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1039\/d2bm01846b","volume":"11","author":"LE 35 Waggoner","year":"2023","unstructured":"35 Waggoner LE, Miyasaki KF, Kwon EJ. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury. Biomater Sci. 2023;11:4238\u201353. https:\/\/doi.org\/10.1039\/d2bm01846b.","journal-title":"Biomater Sci"},{"key":"1857_CR36","doi-asserted-by":"publisher","first-page":"64219","DOI":"10.1021\/acsami.5c17052","volume":"17","author":"S 36 Niederkofler","year":"2025","unstructured":"36 Niederkofler S, et al. Effects of Serum Incubation on Lipid Nanoparticle PEG Shedding, mRNA Retention, and Membrane Interactions. ACS Appl Mater Interfaces. 2025;17:64219\u201331. https:\/\/doi.org\/10.1021\/acsami.5c17052.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1857_CR37","doi-asserted-by":"publisher","unstructured":"37 Li T, et al. Engineered internal architecture of core-shell lipid nanoparticles promotes efficient mRNA endosomal release. Nat Commun. 2026;17. https:\/\/doi.org\/10.1038\/s41467-026-69017-8.","DOI":"10.1038\/s41467-026-69017-8"},{"key":"1857_CR38","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jconrel.2024.11.007","volume":"376","author":"K 38 Wu","year":"2024","unstructured":"38 Wu K, et al. Characterization of mRNA-LNP structural features and mechanisms for enhanced mRNA vaccine immunogenicity. J Control Release. 2024;376:1288\u201399. https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.007.","journal-title":"J Control Release"},{"key":"1857_CR39","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.apsb.2025.11.023","volume":"16","author":"X 39 Xu","year":"2026","unstructured":"39 Xu X, Cui L, Zhang Y, Gu J. Deciphering the biological fate of mRNA-LNP-based biologics: A perspective from tissue to intracellular distribution. Acta Pharm Sinica B. 2026;16:1943\u201370. https:\/\/doi.org\/10.1016\/j.apsb.2025.11.023.","journal-title":"Acta Pharm Sinica B"},{"key":"1857_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-025-09200-x","volume":"644","author":"A 40 Sukalskaia","year":"2025","unstructured":"40 Sukalskaia A, et al. Interactions between TTYH2 and APOE facilitate endosomal lipid transfer. Nature. 2025;644:273\u20139. https:\/\/doi.org\/10.1038\/s41586-025-09200-x.","journal-title":"Nature"},{"key":"1857_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature03205","volume":"433","author":"JD 41 Richter","year":"2005","unstructured":"41 Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005;433:477\u201380. https:\/\/doi.org\/10.1038\/nature03205.","journal-title":"Nature"},{"key":"1857_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10353-6","author":"S 42 Jo","year":"2026","unstructured":"42 Jo S, et al. mRNA vaccines engage unconventional pathways in CD8\u2009+\u2009T cell priming. Nature. 2026. https:\/\/doi.org\/10.1038\/s41586-026-10353-6.","journal-title":"Nature"},{"key":"1857_CR43","doi-asserted-by":"publisher","first-page":"122628","DOI":"10.1016\/j.biomaterials.2024.122628","volume":"310","author":"Q 43 Cao","year":"2024","unstructured":"43 Cao Q, Fang H, Tian H. mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo. Biomaterials. 2024;310:122628. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122628.","journal-title":"Biomaterials"},{"key":"1857_CR44","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E 44 Rohner","year":"2022","unstructured":"44 Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol. 2022;40:1586\u2013600. https:\/\/doi.org\/10.1038\/s41587-022-01491-z.","journal-title":"Nat Biotechnol"},{"key":"1857_CR45","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H 45 Parhiz","year":"2024","unstructured":"45 Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet (London England). 2024;403:1192\u2013204. https:\/\/doi.org\/10.1016\/S0140-6736(23)02444-3.","journal-title":"Lancet (London England)"},{"key":"1857_CR46","doi-asserted-by":"publisher","first-page":"114207","DOI":"10.1016\/j.ejpb.2024.114207","volume":"196","author":"J 46 Walther","year":"2024","unstructured":"46 Walther J, et al. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA\/sgRNA for gene editing in vitro and in vivo. Eur J Pharm Biopharm. 2024;196:114207. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114207.","journal-title":"Eur J Pharm Biopharm"},{"key":"1857_CR47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jcis.2021.11.117","volume":"610","author":"F 47 Sebastiani","year":"2022","unstructured":"47 Sebastiani F, Yanez Arteta M, Lindfors L, Cardenas M. Screening of the binding affinity of serum proteins to lipid nanoparticles in a cell free environment. J Colloid Interface Sci. 2022;610:766\u201374. https:\/\/doi.org\/10.1016\/j.jcis.2021.11.117.","journal-title":"J Colloid Interface Sci"},{"key":"1857_CR48","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.xphs.2023.11.023","volume":"113","author":"U 48 Chheda","year":"2024","unstructured":"48 Chheda U, et al. Factors Affecting Stability of RNA - Temperature, Length, Concentration, pH, and Buffering Species. J Pharm Sci. 2024;113:377\u201385. https:\/\/doi.org\/10.1016\/j.xphs.2023.11.023.","journal-title":"J Pharm Sci"},{"key":"1857_CR49","doi-asserted-by":"publisher","unstructured":"49 Wang J, et al. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. vaccines (Basel). 2024;12. https:\/\/doi.org\/10.3390\/vaccines12101148.","DOI":"10.3390\/vaccines12101148"},{"key":"1857_CR50","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1021\/acs.molpharmaceut.5c00385","volume":"22","author":"Y 50 Bai","year":"2025","unstructured":"50 Bai Y, et al. Recent Advances in mRNA-LNP Delivery Systems for Extrahepatic Organs: A Review. Mol Pharm. 2025;22:4474\u201393. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00385.","journal-title":"Mol Pharm"},{"key":"1857_CR51","doi-asserted-by":"publisher","first-page":"64219","DOI":"10.1021\/acsami.5c17052","volume":"17","author":"S 51 Niederkofler","year":"2025","unstructured":"51 Niederkofler S, et al. Effects of Serum Incubation on Lipid Nanoparticle PEG Shedding, mRNA Retention, and Membrane Interactions. ACS Appl Mater Interfaces. 2025;17:64219\u201331. https:\/\/doi.org\/10.1021\/acsami.5c17052.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1857_CR52","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41563-023-01630-0","volume":"22","author":"LNM 52 Nguyen","year":"2023","unstructured":"52 Nguyen LNM, et al. The exit of nanoparticles from solid tumours. Nat Mater. 2023;22:1261\u201372. https:\/\/doi.org\/10.1038\/s41563-023-01630-0.","journal-title":"Nat Mater"},{"key":"1857_CR53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","volume":"335","author":"KJ 53 Hassett","year":"2021","unstructured":"53 Hassett KJ, et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Control Release. 2021;335:237\u201346. https:\/\/doi.org\/10.1016\/j.jconrel.2021.05.021.","journal-title":"J Control Release"},{"key":"1857_CR54","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1021\/acsnano.4c09399","volume":"19","author":"M 54 Gao","year":"2025","unstructured":"54 Gao M, et al. Deciphering the Role of PEGylation on the Lipid Nanoparticle-Mediated mRNA Delivery to the Liver. ACS Nano. 2025;19:5966\u201378. https:\/\/doi.org\/10.1021\/acsnano.4c09399.","journal-title":"ACS Nano"},{"key":"1857_CR55","doi-asserted-by":"publisher","unstructured":"55 Lee E et al. Elasticity-driven nanomechanical interaction to improve the targeting ability of lipid nanoparticles in the malignant tumor microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12, e2502073. https:\/\/doi.org\/10.1002\/advs.202502073.","DOI":"10.1002\/advs.202502073"},{"key":"1857_CR56","doi-asserted-by":"publisher","unstructured":"Moore ST, et al. Multiplexed lipid nanoparticle barcoding reveals tissue-dynamic kinetic insights and enriched cellular tropism in hepatic zones. Nat Commun. 2026;17. https:\/\/doi.org\/10.1038\/s41467-025-68103-7.","DOI":"10.1038\/s41467-025-68103-7"},{"key":"1857_CR57","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41565-025-01975-4","volume":"20","author":"A 57 Chan","year":"2025","unstructured":"57 Chan A, et al. Designing lipid nanoparticles using a transformer-based neural network. Nat Nanotechnol. 2025;20:1491\u2013501. https:\/\/doi.org\/10.1038\/s41565-025-01975-4.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-026-03109-0","author":"M 58 Zhou","year":"2026","unstructured":"58 Zhou M, et al. A multiobjective AI model for LNP engineering enhances tissue-selective mRNA delivery. Nat Biotechnol. 2026. https:\/\/doi.org\/10.1038\/s41587-026-03109-0.","journal-title":"Nat Biotechnol"},{"key":"1857_CR59","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41587-024-02470-2","volume":"43","author":"H 59 Kim","year":"2025","unstructured":"59 Kim H, et al. Lipid nanoparticle-mediated mRNA delivery to CD34(+) cells in rhesus monkeys. Nat Biotechnol. 2025;43:1813\u201320. https:\/\/doi.org\/10.1038\/s41587-024-02470-2.","journal-title":"Nat Biotechnol"},{"key":"1857_CR60","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","volume":"9","author":"N 60 Veiga","year":"2018","unstructured":"60 Veiga N, et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat Commun. 2018;9:4493. https:\/\/doi.org\/10.1038\/s41467-018-06936-1.","journal-title":"Nat Commun"},{"key":"1857_CR61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q 61 Cheng","year":"2020","unstructured":"61 Cheng Q, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15:313\u201320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR62","doi-asserted-by":"publisher","unstructured":"62 LoPresti ST, Arral ML, Chaudhary N, Whitehead KA. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J Control Release. 2022;345:819\u201331. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.046.","DOI":"10.1016\/j.jconrel.2022.03.046"},{"key":"1857_CR63","doi-asserted-by":"publisher","first-page":"113737","DOI":"10.1016\/j.jconrel.2025.113737","volume":"382","author":"X 63 Liang","year":"2025","unstructured":"63 Liang X, et al. Dimethylamino-based synthetic lipidoid nanoparticles for selective mRNA delivery to splenic antigen-presenting cells. J Control Release. 2025;382:113737. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113737.","journal-title":"J Control Release"},{"key":"1857_CR64","doi-asserted-by":"publisher","first-page":"e12535","DOI":"10.1002\/advs.202512535","volume":"13","author":"Q 64 Yin","year":"2026","unstructured":"64 Yin Q, Zhang C, Li J, Huang K, Qiu MA. Rationally Engineered Spleen-Tropic One-Component Lipid-mRNA Complex (OncoLRC) for Cancer Vaccines. Advanced science (Weinheim. Baden-Wurttemberg Germany). 2026;13:e12535. https:\/\/doi.org\/10.1002\/advs.202512535.","journal-title":"Baden-Wurttemberg Germany)"},{"key":"1857_CR65","doi-asserted-by":"publisher","first-page":"eady6460","DOI":"10.1126\/sciadv.ady6460","volume":"11","author":"Y 65 Zhao","year":"2025","unstructured":"65 Zhao Y, et al. Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation. Sci Adv. 2025;11:eady6460. https:\/\/doi.org\/10.1126\/sciadv.ady6460.","journal-title":"Sci Adv"},{"key":"1857_CR66","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","volume":"375","author":"PS 66 Wei","year":"2024","unstructured":"66 Wei PS, et al. Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies. J Control Release. 2024;375:366\u201388. https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.030.","journal-title":"J Control Release"},{"key":"1857_CR67","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM 67 Kranz","year":"2016","unstructured":"67 Kranz LM, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396\u2013401. https:\/\/doi.org\/10.1038\/nature18300.","journal-title":"Nature"},{"key":"1857_CR68","doi-asserted-by":"publisher","first-page":"217752","DOI":"10.1016\/j.canlet.2025.217752","volume":"625","author":"H 68 Li","year":"2025","unstructured":"68 Li H, Min L, Du H, Wei X, Tong A. Cancer mRNA vaccines: clinical application progress and challenges. Cancer Lett. 2025;625:217752. https:\/\/doi.org\/10.1016\/j.canlet.2025.217752.","journal-title":"Cancer Lett"},{"key":"1857_CR69","doi-asserted-by":"publisher","unstructured":"69 Tavakoli S, et al. Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines. Cancer Cell Int. 2026;26. https:\/\/doi.org\/10.1186\/s12935-026-04265-8.","DOI":"10.1186\/s12935-026-04265-8"},{"key":"1857_CR70","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","volume":"43","author":"F 70 Huber","year":"2025","unstructured":"70 Huber F, et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. 2025;43:1360\u201372. https:\/\/doi.org\/10.1038\/s41587-024-02420-y.","journal-title":"Nat Biotechnol"},{"key":"1857_CR71","doi-asserted-by":"publisher","unstructured":"71 Wu DW, et al. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clin experimental Med. 2024;24. https:\/\/doi.org\/10.1007\/s10238-024-01436-7.","DOI":"10.1007\/s10238-024-01436-7"},{"key":"1857_CR72","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E 72 Blass","year":"2021","unstructured":"72 Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18:215\u201329. https:\/\/doi.org\/10.1038\/s41571-020-00460-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"1857_CR73","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.Cd-24-0158","volume":"14","author":"JF 73 Gainor","year":"2024","unstructured":"73 Gainor JF, et al. T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discov. 2024;14:2209\u201323. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0158.","journal-title":"Cancer Discov"},{"key":"1857_CR74","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1200\/jco-26-00835","volume":"44","author":"A 74 Khattak","year":"2026","unstructured":"74 Khattak A, et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. J Clin oncology: official J Am Soc Clin Oncol. 2026;44:2482\u20139. https:\/\/doi.org\/10.1200\/jco-26-00835.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"1857_CR75","doi-asserted-by":"publisher","unstructured":"75 Zhang Y, et al. Enhanced mRNA vaccine combined with immune checkpoint blockade efficiently suppresses tumor growth and metastasis. J Nanobiotechnol. 2026;24. https:\/\/doi.org\/10.1186\/s12951-026-04358-6.","DOI":"10.1186\/s12951-026-04358-6"},{"key":"1857_CR76","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","volume":"26","author":"Y 76 Wang","year":"2018","unstructured":"76 Wang Y, Zhang L, Xu Z, Miao L, Huang L. mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. Mol therapy: J Am Soc Gene Therapy. 2018;26:420\u201334. https:\/\/doi.org\/10.1016\/j.ymthe.2017.11.009.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"key":"1857_CR77","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40364-024-00692-9","volume":"12","author":"A 77 Shariati","year":"2024","unstructured":"77 Shariati A, et al. mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy. Biomark Res. 2024;12:157. https:\/\/doi.org\/10.1186\/s40364-024-00692-9.","journal-title":"Biomark Res"},{"key":"1857_CR78","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel SA, Minn AJ. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity. 2018;48:417\u201333. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.007.","journal-title":"Immunity"},{"key":"1857_CR79","doi-asserted-by":"publisher","unstructured":"79 Lai I, et al. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J Immunother Cancer. 2018;6. https:\/\/doi.org\/10.1186\/s40425-018-0431-x.","DOI":"10.1186\/s40425-018-0431-x"},{"key":"1857_CR80","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","volume":"345","author":"JQ 80 Liu","year":"2022","unstructured":"80 Liu JQ, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release. 2022;345:306\u201313. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.021.","journal-title":"J Control Release"},{"key":"1857_CR81","doi-asserted-by":"publisher","first-page":"e202500506","DOI":"10.1002\/smsc.202500506","volume":"6","author":"AA 81 Walters","year":"2026","unstructured":"81 Walters AA, et al. Triplet RNA Lipid Nanoparticles for Locoregional Cancer Immunotherapy. Small Sci. 2026;6:e202500506. https:\/\/doi.org\/10.1002\/smsc.202500506.","journal-title":"Small Sci"},{"key":"1857_CR82","doi-asserted-by":"publisher","unstructured":"82 Hewitt SL, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs. Sci Transl Med. 2019;11. https:\/\/doi.org\/10.1126\/scitranslmed.aat9143.","DOI":"10.1126\/scitranslmed.aat9143"},{"key":"1857_CR83","doi-asserted-by":"publisher","first-page":"10635","DOI":"10.1038\/s41467-024-54877-9","volume":"15","author":"AEI 83 Hamouda","year":"2024","unstructured":"83 Hamouda AEI, et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat Commun. 2024;15:10635. https:\/\/doi.org\/10.1038\/s41467-024-54877-9.","journal-title":"Nat Commun"},{"key":"1857_CR84","doi-asserted-by":"publisher","unstructured":"84 Sullivan RJ, et al. First-in-human phase I\/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer. Oncologist. 2025;30. https:\/\/doi.org\/10.1093\/oncolo\/oyaf115.","DOI":"10.1093\/oncolo\/oyaf115"},{"key":"1857_CR85","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1158\/1078-0432.Ccr-25-4643","volume":"32","author":"RF 85 Sweis","year":"2026","unstructured":"85 Sweis RF, et al. Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36\u03b3 plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors. Clin cancer research: official J Am Association Cancer Res. 2026;32:3493\u2013505. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-4643.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"1857_CR86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-25-4865","author":"BA 86 Carneiro","year":"2026","unstructured":"86 Carneiro BA, et al. Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study. Clin cancer research: official J Am Association Cancer Res. 2026. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-4865.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"1857_CR87","unstructured":"87 (!!! INVALID CITATION !!!)."},{"key":"1857_CR88","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41392-023-01479-4","volume":"8","author":"Y 88 Gu","year":"2023","unstructured":"88 Gu Y, et al. Incorporation of a Toll-like receptor 2\/6 agonist potentiates mRNA vaccines against cancer and infectious diseases. Signal Transduct Target therapy. 2023;8:273. https:\/\/doi.org\/10.1038\/s41392-023-01479-4.","journal-title":"Signal Transduct Target therapy"},{"key":"1857_CR89","doi-asserted-by":"publisher","unstructured":"Yu J et al. Targeted LNPs deliver IL-15 superagonists mRNA for precision cancer therapy. Biomaterials 317, 123047. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.123047.","DOI":"10.1016\/j.biomaterials.2024.123047"},{"key":"1857_CR90","doi-asserted-by":"publisher","unstructured":"90 Zhao N, et al. Lipid nanoparticle-mediated co-delivery of IL-33 mRNA and STING agonist modulates the breast cancer microenvironment and potentiates immunotherapy. J Nanobiotechnol. 2026;24. https:\/\/doi.org\/10.1186\/s12951-026-04562-4.","DOI":"10.1186\/s12951-026-04562-4"},{"key":"1857_CR91","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.20.629467","author":"A 91 Amabile","year":"2024","unstructured":"91 Amabile A, et al. Bispecific antibody targeting of lipid nanoparticles. bioRxiv: preprint Serv biology. 2024. https:\/\/doi.org\/10.1101\/2024.12.20.629467.","journal-title":"bioRxiv: preprint Serv biology"},{"key":"1857_CR92","doi-asserted-by":"publisher","first-page":"1494206","DOI":"10.3389\/fimmu.2024.1494206","volume":"15","author":"O 92 Hangiu","year":"2024","unstructured":"92 Hangiu O, et al. Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation. Front Immunol. 2024;15:1494206. https:\/\/doi.org\/10.3389\/fimmu.2024.1494206.","journal-title":"Front Immunol"},{"key":"1857_CR93","doi-asserted-by":"publisher","first-page":"11111","DOI":"10.1038\/s41467-025-66087-y","volume":"16","author":"Y 93 Huang","year":"2025","unstructured":"93 Huang Y, et al. Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. Nat Commun. 2025;16:11111. https:\/\/doi.org\/10.1038\/s41467-025-66087-y.","journal-title":"Nat Commun"},{"key":"1857_CR94","doi-asserted-by":"publisher","first-page":"eadl2720","DOI":"10.1126\/scitranslmed.adl2720","volume":"16","author":"CR 94 Stadler","year":"2024","unstructured":"94 Stadler CR, et al. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6. Sci Transl Med. 2024;16:eadl2720. https:\/\/doi.org\/10.1126\/scitranslmed.adl2720.","journal-title":"Sci Transl Med"},{"key":"1857_CR95","doi-asserted-by":"publisher","first-page":"114990","DOI":"10.1016\/j.addr.2023.114990","volume":"200","author":"M 95 Jeong","year":"2023","unstructured":"95 Jeong M, Lee Y, Park J, Jung H, Lee H. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. Adv Drug Deliv Rev. 2023;200:114990. https:\/\/doi.org\/10.1016\/j.addr.2023.114990.","journal-title":"Adv Drug Deliv Rev"},{"key":"1857_CR96","doi-asserted-by":"publisher","unstructured":"96 Wu F et al. Lipid nanoparticles for delivery of CRISPR gene editing components. Small methods 10, e2401632. https:\/\/doi.org\/10.1002\/smtd.202401632.","DOI":"10.1002\/smtd.202401632"},{"key":"1857_CR97","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1093\/neuonc\/noaf162","volume":"27","author":"Y 97 Zhang","year":"2025","unstructured":"97 Zhang Y, et al. Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma. Neurooncology. 2025;27:2812\u201327. https:\/\/doi.org\/10.1093\/neuonc\/noaf162.","journal-title":"Neurooncology"},{"key":"1857_CR98","doi-asserted-by":"publisher","unstructured":"98 Rosenblum D, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020;6. https:\/\/doi.org\/10.1126\/sciadv.abc9450.","DOI":"10.1126\/sciadv.abc9450"},{"key":"1857_CR99","doi-asserted-by":"publisher","first-page":"101402","DOI":"10.1016\/j.omtm.2024.101402","volume":"33","author":"BJ 99 Parrett","year":"2025","unstructured":"99 Parrett BJ, Yamaoka S, Barry MA. Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites. Mol therapy Methods Clin Dev. 2025;33:101402. https:\/\/doi.org\/10.1016\/j.omtm.2024.101402.","journal-title":"Mol therapy Methods Clin Dev"},{"key":"1857_CR100","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","volume":"20","author":"MZ 100 Chen","year":"2025","unstructured":"100 Chen MZ, et al. A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles. Nat Nanotechnol. 2025;20:1273\u201384. https:\/\/doi.org\/10.1038\/s41565-025-01954-9.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR101","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1038\/s41596-025-01330-w","volume":"21","author":"HC 101 Geisler","year":"2026","unstructured":"101 Geisler HC, Battistini E, Thatte AS, Padilla MS, Mitchell MJ. Preparation of targeted lipid nanoparticles for precision nucleic acid delivery. Nat Protoc. 2026;21:4133\u201368. https:\/\/doi.org\/10.1038\/s41596-025-01330-w.","journal-title":"Nat Protoc"},{"key":"1857_CR102","doi-asserted-by":"publisher","first-page":"113684","DOI":"10.1016\/j.jconrel.2025.113684","volume":"382","author":"X 102 Hou","year":"2025","unstructured":"102 Hou X, et al. Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L\/Flt3L mRNA-mediated dendritic cell activation. J Control Release. 2025;382:113684. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113684.","journal-title":"J Control Release"},{"key":"1857_CR103","doi-asserted-by":"publisher","first-page":"125843","DOI":"10.1016\/j.ijpharm.2025.125843","volume":"681","author":"J 103 Jin","year":"2025","unstructured":"103 Jin J, et al. Co-delivery of IL-12 mRNA and small-molecule prodrug with lung-tropic lipid nanoparticles for synergistic cancer therapy. Int J Pharm. 2025;681:125843. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125843.","journal-title":"Int J Pharm"},{"key":"1857_CR104","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/cm9.0000000000002549","volume":"136","author":"Z 104 Yang","year":"2023","unstructured":"104 Yang Z, Wang Y. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies. Chin Med J. 2023;136:2285\u201396. https:\/\/doi.org\/10.1097\/cm9.0000000000002549.","journal-title":"Chin Med J"},{"key":"1857_CR105","doi-asserted-by":"publisher","first-page":"102520","DOI":"10.1016\/j.omtn.2025.102520","volume":"36","author":"B 105 Dietmair","year":"2025","unstructured":"105 Dietmair B, et al. Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers. Mol therapy Nucleic acids. 2025;36:102520. https:\/\/doi.org\/10.1016\/j.omtn.2025.102520.","journal-title":"Mol therapy Nucleic acids"},{"key":"1857_CR106","doi-asserted-by":"publisher","first-page":"2637266","DOI":"10.1080\/10717544.2026.2637266","volume":"33","author":"S 106 Shah","year":"2026","unstructured":"106 Shah S, et al. Lipid nanoparticles with aptamers enable targeted mRNA delivery to CD4\u207a T cells. Drug Delivery. 2026;33:2637266. https:\/\/doi.org\/10.1080\/10717544.2026.2637266.","journal-title":"Drug Delivery"},{"key":"1857_CR107","doi-asserted-by":"publisher","first-page":"eaec3436","DOI":"10.1126\/sciimmunol.aec3436","volume":"11","author":"AR 107 Corrigan","year":"2026","unstructured":"107 Corrigan AR, et al. In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs. Sci Immunol. 2026;11:eaec3436. https:\/\/doi.org\/10.1126\/sciimmunol.aec3436.","journal-title":"Sci Immunol"},{"key":"1857_CR108","doi-asserted-by":"publisher","unstructured":"108 Liu Y, Ding LWX, Xu Z, Wang Z. First-in-human study of in vivo CAR-T therapy GT801 in adults with relapsed or refractory CD19-positive B-cell hematologic malignancies. J Clin Oncol. 2026;44. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.707.","DOI":"10.1200\/JCO.2026.44.16_suppl.707"},{"key":"1857_CR109","doi-asserted-by":"publisher","first-page":"e01475","DOI":"10.1002\/adhm.202501475","volume":"15","author":"M 109 Wang","year":"2026","unstructured":"109 Wang M, et al. Co-Delivery of Multiple RNAs via Lipid Nanoparticles Enables Precise Gene Editing of CAR-T Cells. Adv Healthc Mater. 2026;15:e01475. https:\/\/doi.org\/10.1002\/adhm.202501475.","journal-title":"Adv Healthc Mater"},{"key":"1857_CR110","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D 110 Bitounis","year":"2024","unstructured":"110 Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discov. 2024;23:281\u2013300. https:\/\/doi.org\/10.1038\/s41573-023-00859-3.","journal-title":"Nat Rev Drug Discov"},{"key":"1857_CR111","doi-asserted-by":"publisher","unstructured":"111 Golubovskaya V, et al. CAR-NK Cells Generated with mRNA-LNPs kill tumor target cells in vitro and in vivo. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms241713364.","DOI":"10.3390\/ijms241713364"},{"key":"1857_CR112","doi-asserted-by":"publisher","unstructured":"112 Shen J, et al. Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia. J experimental Clin cancer research: CR. 2026;45. https:\/\/doi.org\/10.1186\/s13046-026-03689-4.","DOI":"10.1186\/s13046-026-03689-4"},{"key":"1857_CR113","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41565-024-01682-6","volume":"19","author":"D Bitounis","year":"2024","unstructured":"Bitounis D, Amiji MM. Lipid nanoparticles target haematopoietic stem cells. Nat Nanotechnol. 2024;19:1249\u201350. https:\/\/doi.org\/10.1038\/s41565-024-01682-6.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR114","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.ade6967","volume":"381","author":"L 114 Breda","year":"2023","unstructured":"114 Breda L, et al. In vivo hematopoietic stem cell modification by mRNA delivery. Sci (New York N Y). 2023;381:436\u201343. https:\/\/doi.org\/10.1126\/science.ade6967.","journal-title":"Sci (New York N Y)"},{"key":"1857_CR115","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1016\/j.ymthe.2025.03.018","volume":"33","author":"TE 115 Papp","year":"2025","unstructured":"115 Papp TE, et al. CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery. Mol therapy: J Am Soc Gene Therapy. 2025;33:3195\u2013208. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.018.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"key":"1857_CR116","doi-asserted-by":"publisher","first-page":"105423","DOI":"10.1016\/j.exphem.2026.105423","volume":"158","author":"T 116 Hiraki","year":"2026","unstructured":"116 Hiraki T, et al. Development of hematopoietic stem cell-targeted lipid nanoparticles through lipid composition optimization. Exp Hematol. 2026;158:105423. https:\/\/doi.org\/10.1016\/j.exphem.2026.105423.","journal-title":"Exp Hematol"},{"key":"1857_CR117","doi-asserted-by":"publisher","first-page":"eadd4623","DOI":"10.1126\/sciadv.add4623","volume":"9","author":"M Herrera-Barrera","year":"2023","unstructured":"117, Herrera-Barrera M, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv. 2023;9:eadd4623. https:\/\/doi.org\/10.1126\/sciadv.add4623.","journal-title":"Sci Adv"},{"key":"1857_CR118","doi-asserted-by":"publisher","first-page":"9926","DOI":"10.1021\/jacs.2c02706","volume":"144","author":"L 118 Xue","year":"2022","unstructured":"118 Xue L, et al. Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment. J Am Chem Soc. 2022;144:9926\u201337. https:\/\/doi.org\/10.1021\/jacs.2c02706.","journal-title":"J Am Chem Soc"},{"key":"1857_CR119","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41565-024-01847-3","volume":"20","author":"SRJ Hofstraat","year":"2025","unstructured":"Hofstraat SRJ, et al. Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. Nat Nanotechnol. 2025;20:532\u201342. https:\/\/doi.org\/10.1038\/s41565-024-01847-3.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR120","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","volume":"20","author":"CY 120 Chen","year":"2020","unstructured":"120 Chen CY, et al. Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles. Mol therapy Nucleic acids. 2020;20:534\u201344. https:\/\/doi.org\/10.1016\/j.omtn.2020.03.015.","journal-title":"Mol therapy Nucleic acids"},{"key":"1857_CR121","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/gt.2016.46","volume":"23","author":"F 121 DeRosa","year":"2016","unstructured":"121 DeRosa F, et al. Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther. 2016;23:699\u2013707. https:\/\/doi.org\/10.1038\/gt.2016.46.","journal-title":"Gene Ther"},{"key":"1857_CR122","doi-asserted-by":"publisher","unstructured":"122 Ramaswamy S et al. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proceedings of the National Academy of Sciences of the United States of America 114, E1941-e1950. https:\/\/doi.org\/10.1073\/pnas.1619653114.","DOI":"10.1073\/pnas.1619653114"},{"key":"1857_CR123","doi-asserted-by":"publisher","first-page":"114520","DOI":"10.1016\/j.jconrel.2025.114520","volume":"390","author":"M 123 Oh","year":"2026","unstructured":"123 Oh M, et al. mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia. J Control Release. 2026;390:114520. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114520.","journal-title":"J Control Release"},{"key":"1857_CR124","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41551-024-01267-7","volume":"8","author":"X 124 Han","year":"2024","unstructured":"124 Han X, et al. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution. Nat biomedical Eng. 2024;8:1412\u201324. https:\/\/doi.org\/10.1038\/s41551-024-01267-7.","journal-title":"Nat biomedical Eng"},{"key":"1857_CR125","doi-asserted-by":"publisher","first-page":"10374","DOI":"10.1021\/acsnano.3c09028","volume":"18","author":"R 125 Holland","year":"2024","unstructured":"125 Holland R, et al. Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance. ACS Nano. 2024;18:10374\u201387. https:\/\/doi.org\/10.1021\/acsnano.3c09028.","journal-title":"ACS Nano"},{"key":"1857_CR126","doi-asserted-by":"publisher","unstructured":"126 Lv K et al. discovery of ketal-ester ionizable lipid nanoparticle with reduced hepatotoxicity, enhanced spleen tropism for mRNA Vaccine Delivery. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11, e2404684. https:\/\/doi.org\/10.1002\/advs.202404684.","DOI":"10.1002\/advs.202404684"},{"key":"1857_CR127","doi-asserted-by":"publisher","unstructured":"127 Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci USA. 2021;118. https:\/\/doi.org\/10.1073\/pnas.2109256118.","DOI":"10.1073\/pnas.2109256118"},{"key":"1857_CR128","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X 128 Wang","year":"2023","unstructured":"128 Wang X, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18:265\u201391. https:\/\/doi.org\/10.1038\/s41596-022-00755-x.","journal-title":"Nat Protoc"},{"key":"1857_CR129","doi-asserted-by":"publisher","first-page":"14137","DOI":"10.1021\/jacs.6c00080","volume":"148","author":"HM 129 Yamagata","year":"2026","unstructured":"129 Yamagata HM, et al. Liver-Detargeted Aromatic Bioreducible mRNA Lipid Nanoparticles Confer Lymph Node Tropism and Robust Antigen-Specific Immunity. J Am Chem Soc. 2026;148:14137\u201350. https:\/\/doi.org\/10.1021\/jacs.6c00080.","journal-title":"J Am Chem Soc"},{"key":"1857_CR130","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","volume":"15","author":"K 130 Su","year":"2024","unstructured":"130 Su K, et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat Commun. 2024;15:5659. https:\/\/doi.org\/10.1038\/s41467-024-50093-7.","journal-title":"Nat Commun"},{"key":"1857_CR131","doi-asserted-by":"publisher","unstructured":"131 Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers 11. https:\/\/doi.org\/10.3390\/cancers11050640.","DOI":"10.3390\/cancers11050640"},{"key":"1857_CR132","doi-asserted-by":"publisher","first-page":"255","DOI":"10.52601\/bpr.2023.230022","volume":"9","author":"Y 132 Lin","year":"2023","unstructured":"132 Lin Y, Cheng Q, Wei T. Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond. Biophys Rep. 2023;9:255\u201378. https:\/\/doi.org\/10.52601\/bpr.2023.230022.","journal-title":"Biophys Rep"},{"key":"1857_CR133","doi-asserted-by":"publisher","first-page":"114365","DOI":"10.1016\/j.jconrel.2025.114365","volume":"388","author":"L 133 Chen","year":"2025","unstructured":"133 Chen L, et al. Cell-specific mRNA delivery via nanobody-functionalized lipid nanoparticles. J Control Release. 2025;388:114365. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114365.","journal-title":"J Control Release"},{"key":"1857_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.08.039","author":"M 134 Wang","year":"2026","unstructured":"134 Wang M, et al. mRNA-encoding CD19-targeting T cell engager for refractory immune thrombocytopenia. Cell. 2026. https:\/\/doi.org\/10.1016\/j.cell.2026.08.039.","journal-title":"Cell"},{"key":"1857_CR135","doi-asserted-by":"publisher","first-page":"42221","DOI":"10.1021\/jacs.5c06028","volume":"147","author":"F 135 Chen","year":"2025","unstructured":"135 Chen F, et al. Ultrasound-Activatable Lipid Nanoplatform for Region-Confined Innate Immune Stimulation and mRNA Vaccination Therapy of Cancer. J Am Chem Soc. 2025;147:42221\u201336. https:\/\/doi.org\/10.1021\/jacs.5c06028.","journal-title":"J Am Chem Soc"},{"key":"1857_CR136","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s41467-024-45537-z","volume":"15","author":"X 136 Han","year":"2024","unstructured":"136 Han X, et al. In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors. Nat Commun. 2024;15:1762. https:\/\/doi.org\/10.1038\/s41467-024-45537-z.","journal-title":"Nat Commun"},{"key":"1857_CR137","doi-asserted-by":"publisher","first-page":"123541","DOI":"10.1016\/j.biomaterials.2025.123541","volume":"324","author":"F 137 Zhao","year":"2026","unstructured":"137 Zhao F, et al. Biodegradable polymers with tertiary amines enhance mRNA delivery of lipid nanoparticles via improved endosomal escape. Biomaterials. 2026;324:123541. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123541.","journal-title":"Biomaterials"},{"key":"1857_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01577-4","author":"Y 138 Zhao","year":"2025","unstructured":"138 Zhao Y, et al. Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids. Nat biomedical Eng. 2025. https:\/\/doi.org\/10.1038\/s41551-025-01577-4.","journal-title":"Nat biomedical Eng"},{"key":"1857_CR139","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","volume":"43","author":"H 139 Chen","year":"2025","unstructured":"139 Chen H, et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat Biotechnol. 2025;43:194\u2013203. https:\/\/doi.org\/10.1038\/s41587-024-02174-7.","journal-title":"Nat Biotechnol"},{"key":"1857_CR140","doi-asserted-by":"publisher","first-page":"1501010","DOI":"10.3389\/fcimb.2024.1501010","volume":"14","author":"S 140 Imani","year":"2024","unstructured":"140 Imani S, et al. Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy. Front Cell Infect Microbiol. 2024;14:1501010. https:\/\/doi.org\/10.3389\/fcimb.2024.1501010.","journal-title":"Front Cell Infect Microbiol"},{"key":"1857_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-01487-y","author":"E 141 Dolgin","year":"2023","unstructured":"141 Dolgin E. Remarkable\u2019 AI tool designs mRNA vaccines that are more potent and stable. Nature. 2023. https:\/\/doi.org\/10.1038\/d41586-023-01487-y.","journal-title":"Nature"},{"key":"1857_CR142","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1038\/s41467-024-49508-2","volume":"15","author":"S Castillo-Hair","year":"2024","unstructured":"142, Castillo-Hair S, et al. Optimizing 5\u2019UTRs for mRNA-delivered gene editing using deep learning. Nat Commun. 2024;15:5284. https:\/\/doi.org\/10.1038\/s41467-024-49508-2.","journal-title":"Nat Commun"},{"key":"1857_CR143","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1021\/acs.accounts.1c00621","volume":"55","author":"SM Castillo-Hair","year":"2022","unstructured":"143, Castillo-Hair SM, Seelig G. Machine Learning for Designing Next-Generation mRNA Therapeutics. Acc Chem Res. 2022;55:24\u201334. https:\/\/doi.org\/10.1021\/acs.accounts.1c00621.","journal-title":"Acc Chem Res"},{"key":"1857_CR144","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s42256-022-00571-8","volume":"4","author":"HK Wayment-Steele","year":"2022","unstructured":"144, Wayment-Steele HK, et al. Deep learning models for predicting RNA degradation via dual crowdsourcing. Nat Mach Intell. 2022;4:1174\u201384. https:\/\/doi.org\/10.1038\/s42256-022-00571-8.","journal-title":"Nat Mach Intell"},{"key":"1857_CR145","doi-asserted-by":"publisher","first-page":"126096","DOI":"10.1016\/j.ijpharm.2025.126096","volume":"684","author":"Y 145 Bahrami","year":"2025","unstructured":"145 Bahrami Y, et al. Applications of artificial intelligence and nanotechnology in vaccine development. Int J Pharm. 2025;684:126096. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.126096.","journal-title":"Int J Pharm"},{"key":"1857_CR146","doi-asserted-by":"publisher","unstructured":"146 Zhao Y, Wang H. Artificial intelligence-driven circRNA vaccine development: multimodal collaborative optimization and a new paradigm for biomedical applications. Brief Bioinform. 2025;26. https:\/\/doi.org\/10.1093\/bib\/bbaf263.","DOI":"10.1093\/bib\/bbaf263"},{"key":"1857_CR147","unstructured":"147 Liao D et al. RNAGen Scape: property-guided, optimized generation of mrna sequences with manifold langevin dynamics. ArXiv (2026)."},{"key":"1857_CR148","doi-asserted-by":"publisher","first-page":"vbaf134","DOI":"10.1093\/bioadv\/vbaf134","volume":"5","author":"S 148 Barazandeh","year":"2025","unstructured":"148 Barazandeh S, Ozden F, Hincer A, Seker UOS, Cicek AE. UTRGAN: learning to generate 5\u2019 UTR sequences for optimized translation efficiency and gene expression. Bioinf Adv. 2025;5:vbaf134. https:\/\/doi.org\/10.1093\/bioadv\/vbaf134.","journal-title":"Bioinf Adv"},{"key":"1857_CR149","doi-asserted-by":"publisher","unstructured":"149 Yang Y et al. Deciphering 3\u2019UTR Mediated gene regulation using interpretable deep representation learning. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11, e2407013. https:\/\/doi.org\/10.1002\/advs.202407013.","DOI":"10.1002\/advs.202407013"},{"key":"1857_CR150","doi-asserted-by":"publisher","first-page":"9957","DOI":"10.1038\/s41467-025-64894-x","volume":"16","author":"Y 150 Li","year":"2025","unstructured":"150 Li Y, et al. Deep generative optimization of mRNA codon sequences for enhanced mRNA translation and therapeutic efficacy. Nat Commun. 2025;16:9957. https:\/\/doi.org\/10.1038\/s41467-025-64894-x.","journal-title":"Nat Commun"},{"key":"1857_CR151","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41589-025-02074-0","volume":"22","author":"Z 151 Liu","year":"2026","unstructured":"151 Liu Z, Dong Y. AI-powered design accelerates the development of mRNA therapeutics. Nat Chem Biol. 2026;22:15\u20136. https:\/\/doi.org\/10.1038\/s41589-025-02074-0.","journal-title":"Nat Chem Biol"},{"key":"1857_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-026-01434-8","author":"S 152 Ghosh","year":"2026","unstructured":"152 Ghosh S, et al. Unified Sequential Template Amplification and Transcription-a fully synthetic mRNA manufacturing platform. NPJ vaccines. 2026. https:\/\/doi.org\/10.1038\/s41541-026-01434-8.","journal-title":"NPJ vaccines"},{"key":"1857_CR153","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s42256-026-01213-z","volume":"8","author":"Y 153 Chu","year":"2026","unstructured":"153 Chu Y, et al. Programmable RNA translation through deep learning-driven IRES discovery and de novo generation. Nat Mach Intell. 2026;8:559\u201374. https:\/\/doi.org\/10.1038\/s42256-026-01213-z.","journal-title":"Nat Mach Intell"},{"key":"1857_CR154","doi-asserted-by":"publisher","first-page":"9205","DOI":"10.1038\/s41467-025-64257-6","volume":"16","author":"S 154 Golojuch","year":"2025","unstructured":"154 Golojuch S, Largey B, El-Sagheer AH, Brown T. Enhancing cap-independent translation of linear mRNA. Nat Commun. 2025;16:9205. https:\/\/doi.org\/10.1038\/s41467-025-64257-6.","journal-title":"Nat Commun"},{"key":"1857_CR155","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.omtm.2020.03.019","volume":"17","author":"N 155 Sultana","year":"2020","unstructured":"155 Sultana N, et al. Optimization of 5\u2019 Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury. Mol therapy Methods Clin Dev. 2020;17:622\u201333. https:\/\/doi.org\/10.1016\/j.omtm.2020.03.019.","journal-title":"Mol therapy Methods Clin Dev"},{"key":"1857_CR156","doi-asserted-by":"publisher","first-page":"eadr8470","DOI":"10.1126\/science.adr8470","volume":"390","author":"H 156 Zhang","year":"2025","unstructured":"156 Zhang H, et al. Deep generative models design mRNA sequences with enhanced translational capacity and stability. Sci (New York N Y). 2025;390:eadr8470. https:\/\/doi.org\/10.1126\/science.adr8470.","journal-title":"Sci (New York N Y)"},{"key":"1857_CR157","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41565-025-01975-4","volume":"20","author":"A 157 Chan","year":"2025","unstructured":"157 Chan A, et al. Designing lipid nanoparticles using a transformer-based neural network. Nat Nanotechnol. 2025;20:1491\u2013501. https:\/\/doi.org\/10.1038\/s41565-025-01975-4.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR158","doi-asserted-by":"publisher","first-page":"36106","DOI":"10.1021\/acsnano.4c15013","volume":"19","author":"M 158 Sela","year":"2025","unstructured":"158 Sela M, et al. AI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism. ACS Nano. 2025;19:36106\u201328. https:\/\/doi.org\/10.1021\/acsnano.4c15013.","journal-title":"ACS Nano"},{"key":"1857_CR159","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1021\/acs.molpharmaceut.4c00925","volume":"22","author":"Y 159 Yuan","year":"2025","unstructured":"159 Yuan Y, et al. Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics. Mol Pharm. 2025;22:1142\u201359. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00925.","journal-title":"Mol Pharm"},{"key":"1857_CR160","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","volume":"23","author":"B 160 Li","year":"2024","unstructured":"160 Li B, et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat Mater. 2024;23:1002\u20138. https:\/\/doi.org\/10.1038\/s41563-024-01867-3.","journal-title":"Nat Mater"},{"key":"1857_CR161","doi-asserted-by":"publisher","first-page":"103383","DOI":"10.1016\/j.copbio.2025.103383","volume":"96","author":"G 161 Zhang","year":"2025","unstructured":"161 Zhang G, Zuo Z, Wang J, Gong N, Liang XJ. Ionizable lipids empowered with artificial intelligence for mRNA delivery. Curr Opin Biotechnol. 2025;96:103383. https:\/\/doi.org\/10.1016\/j.copbio.2025.103383.","journal-title":"Curr Opin Biotechnol"},{"key":"1857_CR162","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.apsb.2025.11.029","volume":"16","author":"K 162 Su","year":"2026","unstructured":"162 Su K, Qiu J, Xu T, Liu S. Artificial intelligence-guided design of lipid nanoparticles for mRNA delivery. Acta Pharm Sinica B. 2026;16:709\u201327. https:\/\/doi.org\/10.1016\/j.apsb.2025.11.029.","journal-title":"Acta Pharm Sinica B"},{"key":"1857_CR163","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41578-025-00831-0","volume":"11","author":"AR 163 Hanna","year":"2026","unstructured":"163 Hanna AR, Issadore DA, Mitchell MJ. High-throughput platforms for machine learning-guided lipid nanoparticle design. Nat Reviews Mater. 2026;11:50\u201364. https:\/\/doi.org\/10.1038\/s41578-025-00831-0.","journal-title":"Nat Reviews Mater"},{"key":"1857_CR164","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y 164 Xu","year":"2024","unstructured":"164 Xu Y, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat Commun. 2024;15:6305. https:\/\/doi.org\/10.1038\/s41467-024-50619-z.","journal-title":"Nat Commun"},{"key":"1857_CR165","doi-asserted-by":"publisher","first-page":"1357217","DOI":"10.3389\/fimmu.2024.1357217","volume":"15","author":"A 165 Kumar","year":"2024","unstructured":"165 Kumar A, Dixit S, Srinivasan K, M, D., Vincent P. Personalized cancer vaccine design using AI-powered technologies. Front Immunol. 2024;15:1357217. https:\/\/doi.org\/10.3389\/fimmu.2024.1357217.","journal-title":"Front Immunol"},{"key":"1857_CR166","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/0008-5472.Can-24-2553","volume":"85","author":"J 166 Zeng","year":"2025","unstructured":"166 Zeng J, et al. Leveraging Artificial Intelligence for Neoantigen Prediction. Cancer Res. 2025;85:2376\u201387. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-2553.","journal-title":"Cancer Res"},{"key":"1857_CR167","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","volume":"15","author":"W 167 Wang","year":"2024","unstructured":"167 Wang W, et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. Nat Commun. 2024;15:10804. https:\/\/doi.org\/10.1038\/s41467-024-55072-6.","journal-title":"Nat Commun"},{"key":"1857_CR168","doi-asserted-by":"publisher","unstructured":"Bae SH et al. Rational design of lipid nanoparticles for enhanced mRNA vaccine delivery via machine learning. Small 21, e2405618. https:\/\/doi.org\/10.1002\/smll.202405618.","DOI":"10.1002\/smll.202405618"},{"key":"1857_CR169","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/s41587-024-02490-y","volume":"43","author":"J 169 Witten","year":"2025","unstructured":"169 Witten J, et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat Biotechnol. 2025;43:1790\u20139. https:\/\/doi.org\/10.1038\/s41587-024-02490-y.","journal-title":"Nat Biotechnol"},{"key":"1857_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-026-01640-8","author":"LJ 170 Su","year":"2026","unstructured":"170 Su LJ, et al. Artificial intelligence-guided design of LNPs for in vivo targeted mRNA delivery via analysis of the spatial conformation of ionizable lipids. Nat biomedical Eng. 2026. https:\/\/doi.org\/10.1038\/s41551-026-01640-8.","journal-title":"Nat biomedical Eng"},{"key":"1857_CR171","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/s41565-025-02045-5","volume":"20","author":"S 171 Dong","year":"2025","unstructured":"171 Dong S, et al. A modular mRNA platform for programmable induction of tumour-specific immunogenic cell death. Nat Nanotechnol. 2025;20:1856\u201370. https:\/\/doi.org\/10.1038\/s41565-025-02045-5.","journal-title":"Nat Nanotechnol"},{"key":"1857_CR172","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G 172 Maruggi","year":"2019","unstructured":"172 Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol therapy: J Am Soc Gene Therapy. 2019;27:757\u201372. https:\/\/doi.org\/10.1016\/j.ymthe.2019.01.020.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"key":"1857_CR173","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","volume":"11","author":"PF 173 McKay","year":"2020","unstructured":"173 McKay PF, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun. 2020;11:3523. https:\/\/doi.org\/10.1038\/s41467-020-17409-9.","journal-title":"Nat Commun"},{"key":"1857_CR174","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41467-025-55843-9","volume":"16","author":"CJ 174 Maine","year":"2025","unstructured":"174 Maine CJ, et al. Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers. Nat Commun. 2025;16:456. https:\/\/doi.org\/10.1038\/s41467-025-55843-9.","journal-title":"Nat Commun"},{"key":"1857_CR175","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41417-022-00499-6","volume":"30","author":"GP 175 Dailey","year":"2023","unstructured":"175 Dailey GP, Crosby EJ, Hartman ZC. Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Ther. 2023;30:794\u2013802. https:\/\/doi.org\/10.1038\/s41417-022-00499-6.","journal-title":"Cancer Gene Ther"},{"key":"1857_CR176","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","volume":"30","author":"MA Morse","year":"2023","unstructured":"Morse MA, et al. Clinical trials of self-replicating RNA-based cancer vaccines. Cancer Gene Ther. 2023;30:803\u201311. https:\/\/doi.org\/10.1038\/s41417-023-00587-1.","journal-title":"Cancer Gene Ther"},{"key":"1857_CR177","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E 177 Wilson","year":"2023","unstructured":"177 Wilson E, et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023;389:2233\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2307079.","journal-title":"N Engl J Med"},{"key":"1857_CR178","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41587-023-02101-2","volume":"42","author":"178 First self","year":"2024","unstructured":"178 First self-. amplifying mRNA vaccine approved. Nat Biotechnol. 2024;42:4\u20134. https:\/\/doi.org\/10.1038\/s41587-023-02101-2.","journal-title":"Nat Biotechnol"},{"key":"1857_CR179","doi-asserted-by":"publisher","unstructured":"179 Papukashvili D, et al. Self-amplifying RNA approach for protein replacement therapy. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms232112884.","DOI":"10.3390\/ijms232112884"},{"key":"1857_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.03.026","author":"SJ Miyake-Stoner","year":"2026","unstructured":"180, Miyake-Stoner SJ, et al. Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies. Mol therapy: J Am Soc Gene Therapy. 2026. https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.026.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"key":"1857_CR181","doi-asserted-by":"publisher","unstructured":"181 Ren H et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene\u2013a phase I\/II clinical protocol. Journal of neuro-oncology 64, 147\u2013154. https:\/\/doi.org\/10.1007\/bf02700029.","DOI":"10.1007\/bf02700029"},{"key":"1857_CR182","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbrc.2023.09.016","volume":"680","author":"S 182 Deo","year":"2023","unstructured":"182 Deo S, et al. Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies. Biochem Biophys Res Commun. 2023;680:108\u201318. https:\/\/doi.org\/10.1016\/j.bbrc.2023.09.016.","journal-title":"Biochem Biophys Res Commun"},{"key":"1857_CR183","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41417-022-00435-8","volume":"30","author":"P 183 Aliahmad","year":"2023","unstructured":"183 Aliahmad P, Miyake-Stoner SJ, Geall AJ, Wang NS. Next generation self-replicating RNA vectors for vaccines and immunotherapies. Cancer Gene Ther. 2023;30:785\u201393. https:\/\/doi.org\/10.1038\/s41417-022-00435-8.","journal-title":"Cancer Gene Ther"},{"key":"1857_CR184","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ymthe.2025.10.038","volume":"34","author":"H 184 Bahrulolum","year":"2026","unstructured":"184 Bahrulolum H, Rouzbahani FN, Hoseini ZS, Chaharmahali M, Hosseini SM, CircRNA. Unlocking new frontiers in therapeutic and vaccine development. Mol therapy: J Am Soc Gene Therapy. 2026;34:748\u201370. https:\/\/doi.org\/10.1016\/j.ymthe.2025.10.038.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"key":"1857_CR185","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41568-024-00721-7","volume":"24","author":"VM 185 Conn","year":"2024","unstructured":"185 Conn VM, Chinnaiyan AM, Conn SJ. Circular RNA in cancer. Nat Rev Cancer. 2024;24:597\u2013613. https:\/\/doi.org\/10.1038\/s41568-024-00721-7.","journal-title":"Nat Rev Cancer"},{"key":"1857_CR186","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41587-024-02393-y","volume":"43","author":"H 186 Chen","year":"2025","unstructured":"186 Chen H, et al. Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation. Nat Biotechnol. 2025;43:1128\u201343. https:\/\/doi.org\/10.1038\/s41587-024-02393-y.","journal-title":"Nat Biotechnol"},{"key":"1857_CR187","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s12276-024-01220-3","volume":"56","author":"HJ 187 Hwang","year":"2024","unstructured":"187 Hwang HJ, Kim YK. Molecular mechanisms of circular RNA translation. Exp Mol Med. 2024;56:1272\u201380. https:\/\/doi.org\/10.1038\/s12276-024-01220-3.","journal-title":"Exp Mol Med"},{"key":"1857_CR188","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","volume":"41","author":"R 188 Chen","year":"2023","unstructured":"188 Chen R, et al. Engineering circular RNA for enhanced protein production. Nat Biotechnol. 2023;41:262\u201372. https:\/\/doi.org\/10.1038\/s41587-022-01393-0.","journal-title":"Nat Biotechnol"},{"key":"1857_CR189","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1038\/s41467-022-31327-y","volume":"13","author":"X 189 Fan","year":"2022","unstructured":"189 Fan X, Yang Y, Chen C, Wang Z. Pervasive translation of circular RNAs driven by short IRES-like elements. Nat Commun. 2022;13:3751. https:\/\/doi.org\/10.1038\/s41467-022-31327-y.","journal-title":"Nat Commun"},{"key":"1857_CR190","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/cr.2017.31","volume":"27","author":"Y 190 Yang","year":"2017","unstructured":"190 Yang Y, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27:626\u201341. https:\/\/doi.org\/10.1038\/cr.2017.31.","journal-title":"Cell Res"},{"key":"1857_CR191","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41587-025-02561-8","volume":"44","author":"K 191 Fukuchi","year":"2026","unstructured":"191 Fukuchi K, et al. Internal cap-initiated translation for efficient protein production from circular mRNA. Nat Biotechnol. 2026;44:120\u201332. https:\/\/doi.org\/10.1038\/s41587-025-02561-8.","journal-title":"Nat Biotechnol"},{"key":"1857_CR192","doi-asserted-by":"publisher","unstructured":"192 Zheng X, et al. Development and application of an uncapped mRNA platform. Ann Med. 2025;57. https:\/\/doi.org\/10.1080\/07853890.2024.2437046.","DOI":"10.1080\/07853890.2024.2437046"},{"key":"1857_CR193","doi-asserted-by":"publisher","unstructured":"193 Wesselhoeft RA et al. RNA Circularization diminishes immunogenicity and can extend translation duration In Vivo. mol cell 74, 508\u2013520 e504. https:\/\/doi.org\/10.1016\/j.molcel.2019.02.015.","DOI":"10.1016\/j.molcel.2019.02.015"},{"key":"1857_CR194","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","volume":"8","author":"D 194 Niu","year":"2023","unstructured":"194 Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. Signal Transduct Target therapy. 2023;8:341. https:\/\/doi.org\/10.1038\/s41392-023-01561-x.","journal-title":"Signal Transduct Target therapy"},{"key":"1857_CR195","doi-asserted-by":"publisher","first-page":"e2302191120","DOI":"10.1073\/pnas.2302191120","volume":"120","author":"L 195 Amaya","year":"2023","unstructured":"195 Amaya L, et al. Circular RNA vaccine induces potent T cell responses. Proc Natl Acad Sci USA. 2023;120:e2302191120. https:\/\/doi.org\/10.1073\/pnas.2302191120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1857_CR196","doi-asserted-by":"publisher","unstructured":"196 Gong Z, et al. Recent advances and perspectives on the development of circular RNA cancer vaccines. NPJ vaccines. 2025;10. https:\/\/doi.org\/10.1038\/s41541-025-01097-x.","DOI":"10.1038\/s41541-025-01097-x"},{"key":"1857_CR197","doi-asserted-by":"publisher","unstructured":"197 Qu L et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728\u20131744 e1716. https:\/\/doi.org\/10.1016\/j.cell.2022.03.044.","DOI":"10.1016\/j.cell.2022.03.044"},{"key":"1857_CR198","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.7150\/thno.77350","volume":"12","author":"H 198 Li","year":"2022","unstructured":"198 Li H, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics. 2022;12:6422\u201336. https:\/\/doi.org\/10.7150\/thno.77350.","journal-title":"Theranostics"},{"key":"1857_CR199","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41551-025-01344-5","volume":"9","author":"Y 199 Zhang","year":"2025","unstructured":"199 Zhang Y, et al. Small circular RNAs as vaccines for cancer immunotherapy. Nat biomedical Eng. 2025;9:249\u201367. https:\/\/doi.org\/10.1038\/s41551-025-01344-5.","journal-title":"Nat biomedical Eng"},{"key":"1857_CR200","doi-asserted-by":"publisher","unstructured":"200 Li H, et al. Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy. Signal Transduct Target therapy. 2025;10. https:\/\/doi.org\/10.1038\/s41392-025-02191-1.","DOI":"10.1038\/s41392-025-02191-1"},{"key":"1857_CR201","doi-asserted-by":"publisher","first-page":"102250","DOI":"10.1016\/j.xcrm.2025.102250","volume":"6","author":"Y 201 Wang","year":"2025","unstructured":"201 Wang Y, et al. Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting. Cell Rep Med. 2025;6:102250. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102250.","journal-title":"Cell Rep Med"},{"key":"1857_CR202","doi-asserted-by":"publisher","first-page":"102209","DOI":"10.1016\/j.xcrm.2025.102209","volume":"6","author":"Z 202 Zhang","year":"2025","unstructured":"202 Zhang Z, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep Med. 2025;6:102209. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102209.","journal-title":"Cell Rep Med"},{"key":"1857_CR203","doi-asserted-by":"publisher","unstructured":"203 Cai J, et al. Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer. Experimental Hematol Oncol. 2025;14. https:\/\/doi.org\/10.1186\/s40164-025-00625-8.","DOI":"10.1186\/s40164-025-00625-8"},{"key":"1857_CR204","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41587-021-01180-3","volume":"40","author":"Z 204 Yi","year":"2022","unstructured":"204 Yi Z, et al. Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. Nat Biotechnol. 2022;40:946\u201355. https:\/\/doi.org\/10.1038\/s41587-021-01180-3.","journal-title":"Nat Biotechnol"},{"key":"1857_CR205","doi-asserted-by":"publisher","first-page":"121570","DOI":"10.1016\/j.biomaterials.2022.121570","volume":"286","author":"M 205 Ripoll","year":"2022","unstructured":"205 Ripoll M, et al. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates. Biomaterials. 2022;286:121570. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121570.","journal-title":"Biomaterials"},{"key":"1857_CR206","doi-asserted-by":"publisher","first-page":"104066","DOI":"10.1016\/j.xphs.2025.104066","volume":"115","author":"HJ 206 Coleman","year":"2026","unstructured":"206 Coleman HJ, et al. Lipid-free, thermostable mRNA vaccines prepared using atomic layer deposition. J Pharm Sci. 2026;115:104066. https:\/\/doi.org\/10.1016\/j.xphs.2025.104066.","journal-title":"J Pharm Sci"},{"key":"1857_CR207","doi-asserted-by":"publisher","unstructured":"207 Chen X, et al. Loss of internal structural order induced by freezing and Lyophilization correlates with reduced in vitro activity of mRNA lipid nanoparticles. J Control Release. 2026;115148. https:\/\/doi.org\/10.1016\/j.jconrel.2026.115148.","DOI":"10.1016\/j.jconrel.2026.115148"},{"key":"1857_CR208","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1021\/acs.molpharmaceut.4c00826","volume":"21","author":"U 208 Kafle","year":"2024","unstructured":"208 Kafle U, Truong HQ, Nguyen CTG, Meng F. Development of Thermally Stable mRNA-LNP Delivery Systems: Current Progress and Future Prospects. Mol Pharm. 2024;21:5944\u201359. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00826.","journal-title":"Mol Pharm"},{"key":"1857_CR209","doi-asserted-by":"publisher","unstructured":"209 Cheng X, et al. Freezing induced incorporation of betaine in lipid nanoparticles enhances mRNA delivery. Nat Commun. 2025;16. https:\/\/doi.org\/10.1038\/s41467-025-60040-9.","DOI":"10.1038\/s41467-025-60040-9"},{"key":"1857_CR210","doi-asserted-by":"publisher","unstructured":"210 Zhou Y, Wei Y, Tian X, Wei X. Cancer vaccines: current status and future directions. J Hematol Oncol. 2025;18. https:\/\/doi.org\/10.1186\/s13045-025-01670-w.","DOI":"10.1186\/s13045-025-01670-w"},{"key":"1857_CR211","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41591-026-04241-9","volume":"32","author":"JB 211 Haanen","year":"2026","unstructured":"211 Haanen JB, Schumacher TNM, Kagan JC, Fritsch EF, Wu CJ. Clinical development of cancer vaccines. Nat Med. 2026;32:828\u201340. https:\/\/doi.org\/10.1038\/s41591-026-04241-9.","journal-title":"Nat Med"},{"key":"1857_CR212","doi-asserted-by":"publisher","first-page":"114000","DOI":"10.1016\/j.addr.2021.114000","volume":"179","author":"S 212 Jain","year":"2021","unstructured":"212 Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev. 2021;179:114000. https:\/\/doi.org\/10.1016\/j.addr.2021.114000.","journal-title":"Adv Drug Deliv Rev"},{"key":"1857_CR213","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1016\/j.immuni.2023.11.009","volume":"56","author":"BD 213 Brown","year":"2023","unstructured":"213 Brown BD, Fauci AS, Belkaid Y, Merad M. RNA vaccines: A transformational advance. Immunity. 2023;56:2665\u20139. https:\/\/doi.org\/10.1016\/j.immuni.2023.11.009.","journal-title":"Immunity"},{"key":"1857_CR214","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS 214 Rosa","year":"2021","unstructured":"214 Rosa SS, Prazeres DMF, Azevedo AM, Marques M. P. C. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021;39:2190\u2013200. https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.038.","journal-title":"Vaccine"},{"key":"1857_CR215","doi-asserted-by":"publisher","unstructured":"de Abreu L. A. J. Unpacking the mRNA supply chain: challenges and opportunities for global health. Vaccines (Basel) 14. https:\/\/doi.org\/10.3390\/vaccines14040324.","DOI":"10.3390\/vaccines14040324"},{"key":"1857_CR216","doi-asserted-by":"publisher","unstructured":"Gupta D, Shaz B. Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility. J translational Med. 2025;23. https:\/\/doi.org\/10.1186\/s12967-025-06400-x.","DOI":"10.1186\/s12967-025-06400-x"},{"key":"1857_CR217","doi-asserted-by":"publisher","unstructured":"217 Skerritt JH. Considerations for mRNA product development, regulation and deployment across the lifecycle. Vaccines (Basel). 2025;13. https:\/\/doi.org\/10.3390\/vaccines13050473.","DOI":"10.3390\/vaccines13050473"},{"key":"1857_CR218","doi-asserted-by":"publisher","first-page":"1793322","DOI":"10.3389\/fddev.2026.1793322","volume":"6","author":"OP 218 Ugwu","year":"2026","unstructured":"218 Ugwu OP, et al. Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review. Front drug delivery. 2026;6:1793322. https:\/\/doi.org\/10.3389\/fddev.2026.1793322.","journal-title":"Front drug delivery"},{"key":"1857_CR219","doi-asserted-by":"publisher","first-page":"e70041","DOI":"10.1002\/cai2.70041","volume":"4","author":"B 219 Yang","year":"2025","unstructured":"219 Yang B, Liu J, Li Y, Liu X. mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics. Cancer Innov. 2025;4:e70041. https:\/\/doi.org\/10.1002\/cai2.70041.","journal-title":"Cancer Innov"},{"key":"1857_CR220","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.ai.2024.10.011","volume":"166","author":"K 220 Adhikary","year":"2025","unstructured":"220 Adhikary K, et al. Personalized precision: Revolutionizing cancer treatment with mRNA-based vaccines in melanoma therapy. Adv Immunol. 2025;166:137\u201367. https:\/\/doi.org\/10.1016\/bs.ai.2024.10.011.","journal-title":"Adv Immunol"},{"key":"1857_CR221","doi-asserted-by":"publisher","unstructured":"Makkar SK. Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives. Front Genet. 2025;16. https:\/\/doi.org\/10.3389\/fgene.2025.1675209.","DOI":"10.3389\/fgene.2025.1675209"},{"key":"1857_CR222","doi-asserted-by":"publisher","unstructured":"Magoola M, Niazi SK. Current progress and future perspectives of RNA-based cancer vaccines: A 2025 Update. Cancers 17. https:\/\/doi.org\/10.3390\/cancers17111882.","DOI":"10.3390\/cancers17111882"},{"key":"1857_CR223","doi-asserted-by":"publisher","first-page":"11766","DOI":"10.1021\/jacs.4c14474","volume":"147","author":"HS 223 Kim","year":"2025","unstructured":"223 Kim HS, Simpson GG, Fei F, Garris C, Weissleder R. Fluorinated Ribonucleocarbohydrate Nanoparticles Allow Ultraefficient mRNA Delivery and Protein Expression in Tumor-Associated Myeloid Cells. J Am Chem Soc. 2025;147:11766\u201376. https:\/\/doi.org\/10.1021\/jacs.4c14474.","journal-title":"J Am Chem Soc"},{"key":"1857_CR224","doi-asserted-by":"publisher","first-page":"10085","DOI":"10.1039\/d5tb01556a","volume":"13","author":"Y 224 Sui","year":"2025","unstructured":"224 Sui Y, et al. Lipid nanoparticle-mediated targeted mRNA delivery and its application in cancer therapy. J Mater Chem B. 2025;13:10085\u2013117. https:\/\/doi.org\/10.1039\/d5tb01556a.","journal-title":"J Mater Chem B"},{"key":"1857_CR225","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrm.2016.174","volume":"18","author":"SA Gorski","year":"2017","unstructured":"Gorski SA, Vogel J, Doudna JA. RNA-based recognition and targeting: sowing the seeds of specificity. Nat Rev Mol Cell Biol. 2017;18:215\u201328. https:\/\/doi.org\/10.1038\/nrm.2016.174.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1857_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-026-03099-z","author":"A 226 Marks","year":"2026","unstructured":"226 Marks A, et al. mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression. Nat Biotechnol. 2026. https:\/\/doi.org\/10.1038\/s41587-026-03099-z.","journal-title":"Nat Biotechnol"},{"key":"1857_CR227","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10329-6","author":"U 227 Koeber","year":"2026","unstructured":"227 Koeber U, et al. Synthetic super-enhancers enable precision viral immunotherapy. Nature. 2026. https:\/\/doi.org\/10.1038\/s41586-026-10329-6.","journal-title":"Nature"},{"key":"1857_CR228","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ng.3167","volume":"47","author":"S Pott","year":"2015","unstructured":"Pott S, Lieb JD. What are super-enhancers? Nat Genet. 2015;47:8\u201312. https:\/\/doi.org\/10.1038\/ng.3167.","journal-title":"Nat Genet"},{"key":"1857_CR229","doi-asserted-by":"publisher","first-page":"2597629","DOI":"10.1080\/21645515.2025.2597629","volume":"21","author":"Y 229 Yang","year":"2025","unstructured":"229 Yang Y, Sun Y, Kang X, Wang Y. mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation. Hum vaccines immunotherapeutics. 2025;21:2597629. https:\/\/doi.org\/10.1080\/21645515.2025.2597629.","journal-title":"Hum vaccines immunotherapeutics"},{"key":"1857_CR230","doi-asserted-by":"publisher","unstructured":"230 Fang E, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target therapy. 2022;7. https:\/\/doi.org\/10.1038\/s41392-022-00950-y.","DOI":"10.1038\/s41392-022-00950-y"},{"key":"1857_CR231","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","volume":"55","author":"J 231 Lee","year":"2023","unstructured":"231 Lee J, Woodruff MC, Kim EH, Nam J-H. Knife\u2019s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. Exp Mol Med. 2023;55:1305\u201313. https:\/\/doi.org\/10.1038\/s12276-023-00999-x.","journal-title":"Exp Mol Med"},{"key":"1857_CR232","doi-asserted-by":"publisher","unstructured":"232 Takano T, et al. Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. Cell Rep Med. 2022;3. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100631.","DOI":"10.1016\/j.xcrm.2022.100631"},{"key":"1857_CR233","doi-asserted-by":"publisher","unstructured":"233 Li L et al. mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions. MedComm 7, e70700. https:\/\/doi.org\/10.1002\/mco2.70700 (2026).","DOI":"10.1002\/mco2.70700"},{"key":"1857_CR234","doi-asserted-by":"publisher","first-page":"9643","DOI":"10.7150\/thno.118976","volume":"15","author":"X 234 Gao","year":"2025","unstructured":"234 Gao X, et al. Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy. Theranostics. 2025;15:9643\u201362. https:\/\/doi.org\/10.7150\/thno.118976.","journal-title":"Theranostics"},{"key":"1857_CR235","doi-asserted-by":"publisher","first-page":"23289","DOI":"10.1021\/acsnano.4c06160","volume":"18","author":"J 235 Liu","year":"2024","unstructured":"235 Liu J, et al. Low-Dose Mildronate-Derived Lipidoids for Efficient mRNA Vaccine Delivery with Minimal Inflammation Side Effects. ACS Nano. 2024;18:23289\u2013300. https:\/\/doi.org\/10.1021\/acsnano.4c06160.","journal-title":"ACS Nano"},{"key":"1857_CR236","doi-asserted-by":"publisher","unstructured":"236 Zelkoski AE, et al. Pre-vaccination immune profiles and responsiveness to innate stimuli predict reactogenicity and antibody magnitude following mRNA vaccination. Vaccines (Basel). 2025;13. https:\/\/doi.org\/10.3390\/vaccines13070718.","DOI":"10.3390\/vaccines13070718"},{"key":"1857_CR237","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa2516491","volume":"394","author":"I Leroux-Roels","year":"2026","unstructured":"237, Leroux-Roels I, et al. Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. N Engl J Med. 2026;394:1803\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2516491.","journal-title":"N Engl J Med"},{"key":"1857_CR238","doi-asserted-by":"publisher","unstructured":"238 Quan Y, Yang H, Li W, Li L. mRNA vaccines: immunogenicity and quality characteristics. J Nanobiotechnol. 2025;24. https:\/\/doi.org\/10.1186\/s12951-025-03800-5.","DOI":"10.1186\/s12951-025-03800-5"},{"key":"1857_CR239","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.ymthe.2024.12.019","volume":"33","author":"HM 239 Nguyen","year":"2025","unstructured":"239 Nguyen HM, et al. mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions. Mol therapy: J Am Soc Gene Therapy. 2025;33:2872\u201385. https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.019.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"key":"1857_CR240","doi-asserted-by":"publisher","first-page":"e2312026","DOI":"10.1002\/adma.202312026","volume":"36","author":"S Omo-Lamai","year":"2024","unstructured":"240, Omo-Lamai S, et al. Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and Solutions. Adv Mater. 2024;36:e2312026. https:\/\/doi.org\/10.1002\/adma.202312026.","journal-title":"Adv Mater"},{"key":"1857_CR241","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s44222-025-00314-5","volume":"3","author":"S Omo-Lamai","year":"2025","unstructured":"241, Omo-Lamai S, Zamora ME, Mueller BK, Casciano JC, Brenner JS. RNA\u2013lipid nanoparticles for acute critical illnesses. Nat Reviews Bioeng. 2025;3:775\u201390. https:\/\/doi.org\/10.1038\/s44222-025-00314-5.","journal-title":"Nat Reviews Bioeng"},{"key":"1857_CR242","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","volume":"28","author":"X 242 Huang","year":"2022","unstructured":"242 Huang X, et al. The landscape of mRNA nanomedicine. Nat Med. 2022;28:2273\u201387. https:\/\/doi.org\/10.1038\/s41591-022-02061-1.","journal-title":"Nat Med"},{"key":"1857_CR243","doi-asserted-by":"publisher","first-page":"9925","DOI":"10.1021\/acsnano.5c20535","volume":"20","author":"Y 243 Kim","year":"2026","unstructured":"243 Kim Y, et al. Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells. ACS Nano. 2026;20:9925\u201339. https:\/\/doi.org\/10.1021\/acsnano.5c20535.","journal-title":"ACS Nano"},{"key":"1857_CR244","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D 244 Bitounis","year":"2024","unstructured":"244 Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discovery. 2024;23:281\u2013300. https:\/\/doi.org\/10.1038\/s41573-023-00859-3.","journal-title":"Nat Rev Drug Discovery"},{"key":"1857_CR245","doi-asserted-by":"publisher","first-page":"102872","DOI":"10.1016\/j.omtn.2026.102872","volume":"37","author":"AS 245 Thatte","year":"2026","unstructured":"245 Thatte AS, Mitchell MJ. To modify or not to modify: Rethinking mRNA design for CAR T cell engineering. Mol therapy Nucleic acids. 2026;37:102872. https:\/\/doi.org\/10.1016\/j.omtn.2026.102872.","journal-title":"Mol therapy Nucleic acids"},{"key":"1857_CR246","doi-asserted-by":"publisher","unstructured":"246 Hu Q, et al. Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy. Signal Transduct Target therapy. 2025;10. https:\/\/doi.org\/10.1038\/s41392-025-02512-4.","DOI":"10.1038\/s41392-025-02512-4"},{"key":"1857_CR247","doi-asserted-by":"publisher","unstructured":"247 Lu L, Lu X, Luo W. Personalized cancer vaccines: current advances and emerging horizons. Vaccines (Basel). 2025;13. https:\/\/doi.org\/10.3390\/vaccines13121231.","DOI":"10.3390\/vaccines13121231"},{"key":"1857_CR248","doi-asserted-by":"publisher","unstructured":"248 Sheikhlary S, Lopez DH, Moghimi S, Sun B. Recent findings on therapeutic cancer vaccines: an updated review. Biomolecules 14. https:\/\/doi.org\/10.3390\/biom14040503.","DOI":"10.3390\/biom14040503"},{"key":"1857_CR249","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1016\/j.vaccine.2023.10.027","volume":"41","author":"PS 249 Gsell","year":"2023","unstructured":"249 Gsell PS, et al. Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO\/MPP mRNA Technology Transfer Programme meeting report. Vaccine. 2023;41:7307\u201312. https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.027.","journal-title":"Vaccine"},{"key":"1857_CR250","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","volume":"9","author":"Y 250 Shi","year":"2024","unstructured":"250 Shi Y, Shi M, Wang Y, You J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct Target therapy. 2024;9:322. https:\/\/doi.org\/10.1038\/s41392-024-02002-z.","journal-title":"Signal Transduct Target therapy"},{"key":"1857_CR251","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.fmre.2023.02.022","volume":"3","author":"HH 251 Wei","year":"2023","unstructured":"251 Wei HH, Zheng L, Wang Z. mRNA therapeutics: New vaccination and beyond. Fundamental Res. 2023;3:749\u201359. https:\/\/doi.org\/10.1016\/j.fmre.2023.02.022.","journal-title":"Fundamental Res"},{"key":"1857_CR252","doi-asserted-by":"publisher","unstructured":"252 Youssef M, Hitti C, Puppin Chaves Fulber J, Kamen AA. Enabling mRNA therapeutics: current landscape and challenges in manufacturing. Biomolecules. 2023;13. https:\/\/doi.org\/10.3390\/biom13101497.","DOI":"10.3390\/biom13101497"},{"key":"1857_CR253","doi-asserted-by":"publisher","unstructured":"253 Haghmorad D, et al. mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy. Front Bioeng Biotechnol. 2025;13. https:\/\/doi.org\/10.3389\/fbioe.2025.1547025.","DOI":"10.3389\/fbioe.2025.1547025"},{"key":"1857_CR254","doi-asserted-by":"publisher","first-page":"115019","DOI":"10.1016\/j.jconrel.2026.115019","volume":"395","author":"T 254 Ikrar","year":"2026","unstructured":"254 Ikrar T, Muchsin W, Sophian A. mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access. J Control Release. 2026;395:115019. https:\/\/doi.org\/10.1016\/j.jconrel.2026.115019.","journal-title":"J Control Release"},{"key":"1857_CR255","doi-asserted-by":"publisher","first-page":"1738942","DOI":"10.3389\/fpubh.2026.1738942","volume":"14","author":"S 255 Liu","year":"2026","unstructured":"255 Liu S, Zhou T, Wang M, Xiang W, Wu J. Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data. Front Public Health. 2026;14:1738942. https:\/\/doi.org\/10.3389\/fpubh.2026.1738942.","journal-title":"Front Public Health"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01857-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01857-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01857-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:47:28Z","timestamp":1792190848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01857-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":255,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1857"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01857-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"19 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"87"}}